NOVARTIS AG

Explore Novartis’s next earnings amid volatile ECB policy, EU pricing reforms, and rising competition, revealing key cash‑flow strengths and regulatory risks.

Novartis secures FDA approval of Fabhalta, the first oral complement‑inhibitor for IgA nephropathy, offering a new high‑growth treatment pathway with strong clinical data and patient‑centric delivery.

Novartis’s Fabhalta, a novel complement‑inhibitor, earns FDA approval for primary IgA nephropathy, slowing eGFR decline and reducing albuminuria with a strong safety profile.

Novartis’s bold cell‑and‑gene therapy pivot—spending $8.2B R&D, $5B capacity upgrades, and high‑margin 70% projections—positions it to dominate the $110B market by 2030.

How top pharma firms are turning cell‑therapy into a 12 billion‑dollar growth engine—boosting margins, cutting costs, and seizing patent‑cliff opportunities.

China’s expanded medical‑insurance catalogue boosts access to biologics, driving sales up 20‑35% and reshaping pharma strategy for global players.

Novartis shares rise modestly after the U.S. Supreme Court upholds Medicare pricing, while strong Pluvicto trial results boost investor optimism for future oncology growth.

Novartis Q1 2024 earnings miss reveals generic pressure and pipeline promise – a deep dive into pricing, patent cliffs, M&A and future growth.

Novartis eyes 5‑6% revenue growth and a €700‑€900 million NPV for Rhapsido, its first oral CSU therapy, amid strong oncology profits and strategic M&A prospects.

Novartis pulls EU filing for Pluvicto’s expanded prostate‑cancer indication, sparking market, HTA and reimbursement shifts while keeping global growth and pipeline focus strong.